ADAM9 Protein In Pancreatic Neoplasms Development

Pancreatic ductal adenocarcinoma is probably the most lethal cancer, with a median survival of less than 6 months and a 5-year survival rate of less than 5%. The cause of pancreatic ductal adenocarcinoma is unknown, and it resists all currently available treatments. ADAM9 belongs to a family of transmembrane proteins implicated in cell-cell interactions, proteolysis of membrane proteins, and various aspects of carcinogenesis. In this study, we aimed to evaluate the expression and function of ADAM9 in pancreatic cancer. PANC-1, a pancreatic cancer cell line, was treated with short interfering RNAs (siRNA) for ADAM9 to investigate its effect on growth and metastasis. Protein expression in PANC-1 cells after ADAM9 siRNA treatment was detected by western blotting. MTT assays were used to evaluate PANC-1 cell proliferation. The Transwell migration experiments assays, three-dimensional (3D) Matrigel assays, and invasive assays were used to evaluate migration, colony formation and invasiveness after ADAM9 siRNA treatment, respectively, and showed that decreased ADAM9 expression significantly suppressed migration, colony formation and invasiveness of cancer cells. In conclusion, decreased ADAM9 expression can inhibit migration, colony formation and invasion of pancreatic cancer cells. Our study provides preclinical support for chemotherapeutic approaches that target ADAM9 for pancreatic cancer treatment.